Rejlers AB (publ) (STO:REJL.B)
Sweden · Delayed Price · Currency is SEK 192.20
-6.60 (-3.32%)
Aug 1, 2025, 5:29 PM CET
Verve Therapeutics Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 4,596 | 4,431 | 4,088 | 3,513 | 2,899 | 2,367 | Upgrade | |
Revenue Growth (YoY) | 7.49% | 8.38% | 16.38% | 21.19% | 22.47% | 10.77% | Upgrade |
Cost of Revenue | 2,867 | 2,824 | 2,648 | 2,142 | 1,801 | 1,587 | Upgrade |
Gross Profit | 1,728 | 1,607 | 1,440 | 1,372 | 1,098 | 779.9 | Upgrade |
Selling, General & Admin | 1,219 | 1,120 | 1,001 | 960.6 | 823.2 | 580.8 | Upgrade |
Other Operating Expenses | -10.1 | -15.8 | -19 | -10.5 | -8.8 | -0.4 | Upgrade |
Operating Expenses | 1,373 | 1,255 | 1,123 | 1,079 | 929.2 | 684.2 | Upgrade |
Operating Income | 355.4 | 352.6 | 316.6 | 292.5 | 168.4 | 95.7 | Upgrade |
Interest Expense | -31.9 | -28.2 | -30.5 | -11.7 | -9.3 | -13.5 | Upgrade |
Interest & Investment Income | - | 2.7 | 4.9 | 0.9 | 0.8 | 0.7 | Upgrade |
Earnings From Equity Investments | 1 | 1 | 2.4 | 1.5 | 2.5 | 2.3 | Upgrade |
Currency Exchange Gain (Loss) | 2.6 | 2.6 | -9.6 | 8.4 | 14.9 | -18.2 | Upgrade |
Other Non Operating Income (Expenses) | 27.1 | 27.1 | 26.9 | 13.9 | -0.1 | -0.9 | Upgrade |
EBT Excluding Unusual Items | 354.2 | 357.8 | 310.7 | 305.5 | 177.2 | 66.1 | Upgrade |
Merger & Restructuring Charges | -69.8 | -66.1 | -84.7 | -59.7 | -41.2 | -29.1 | Upgrade |
Gain (Loss) on Sale of Assets | 0.7 | 0.7 | 0.7 | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | - | 12.8 | Upgrade |
Pretax Income | 285.1 | 292.4 | 226.7 | 245.8 | 136 | 49.8 | Upgrade |
Income Tax Expense | 70.2 | 70.6 | 41.3 | 49.4 | 25.8 | 17.3 | Upgrade |
Earnings From Continuing Operations | 214.9 | 221.8 | 185.4 | 196.4 | 110.2 | 32.5 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | 252.5 | Upgrade |
Net Income to Company | 214.9 | 221.8 | 185.4 | 196.4 | 110.2 | 285 | Upgrade |
Net Income | 214.9 | 221.8 | 185.4 | 196.4 | 110.2 | 285 | Upgrade |
Net Income to Common | 214.9 | 221.8 | 185.4 | 196.4 | 110.2 | 285 | Upgrade |
Net Income Growth | 7.07% | 19.63% | -5.60% | 78.22% | -61.33% | 267.27% | Upgrade |
Shares Outstanding (Basic) | 22 | 22 | 22 | 20 | 20 | 20 | Upgrade |
Shares Outstanding (Diluted) | 22 | 22 | 22 | 21 | 20 | 20 | Upgrade |
Shares Change (YoY) | -0.53% | 1.99% | 5.40% | 2.08% | 0.07% | 7.92% | Upgrade |
EPS (Basic) | 9.69 | 10.03 | 8.55 | 9.72 | 5.60 | 14.48 | Upgrade |
EPS (Diluted) | 9.69 | 10.03 | 8.55 | 9.55 | 5.47 | 14.15 | Upgrade |
EPS Growth | 7.75% | 17.26% | -10.44% | 74.59% | -61.35% | 240.21% | Upgrade |
Free Cash Flow | 332 | 387.4 | 245.3 | 259.9 | 152.1 | 295.3 | Upgrade |
Free Cash Flow Per Share | 14.96 | 17.52 | 11.32 | 12.64 | 7.55 | 14.67 | Upgrade |
Dividend Per Share | 5.000 | 5.000 | 4.500 | 4.500 | 3.000 | - | Upgrade |
Dividend Growth | 11.11% | 11.11% | - | 50.00% | - | - | Upgrade |
Gross Margin | 37.61% | 36.27% | 35.22% | 39.04% | 37.87% | 32.95% | Upgrade |
Operating Margin | 7.73% | 7.96% | 7.74% | 8.33% | 5.81% | 4.04% | Upgrade |
Profit Margin | 4.68% | 5.01% | 4.54% | 5.59% | 3.80% | 12.04% | Upgrade |
Free Cash Flow Margin | 7.22% | 8.74% | 6.00% | 7.40% | 5.25% | 12.48% | Upgrade |
EBITDA | 447.9 | 430 | 390.7 | 351.2 | 209.5 | 128.9 | Upgrade |
EBITDA Margin | 9.75% | 9.71% | 9.56% | 10.00% | 7.23% | 5.45% | Upgrade |
D&A For EBITDA | 92.5 | 77.4 | 74.1 | 58.7 | 41.1 | 33.2 | Upgrade |
EBIT | 355.4 | 352.6 | 316.6 | 292.5 | 168.4 | 95.7 | Upgrade |
EBIT Margin | 7.73% | 7.96% | 7.74% | 8.33% | 5.81% | 4.04% | Upgrade |
Effective Tax Rate | 24.62% | 24.14% | 18.22% | 20.10% | 18.97% | 34.74% | Upgrade |
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.